4D Molecular Therapeutics, Inc.
FDMT
$10.45
$0.111.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.05M | 85.09M | 90.00K | 15.00K | 14.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.05M | 85.09M | 90.00K | 15.00K | 14.00K |
| Cost of Revenue | 64.98M | 57.51M | 47.24M | 47.95M | 40.70M |
| Gross Profit | -61.93M | 27.58M | -47.15M | -47.94M | -40.69M |
| SG&A Expenses | 11.69M | 12.77M | 11.84M | 11.52M | 12.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.67M | 70.28M | 59.08M | 59.47M | 53.64M |
| Operating Income | -73.62M | 14.82M | -58.99M | -59.46M | -53.62M |
| Income Before Tax | -68.76M | 19.40M | -56.88M | -54.66M | -47.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.76M | 19.40M | -56.88M | -54.66M | -47.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.76M | 19.40M | -56.88M | -54.66M | -47.97M |
| EBIT | -73.62M | 14.82M | -58.99M | -59.46M | -53.62M |
| EBITDA | -72.35M | 16.03M | -57.72M | -58.29M | -52.57M |
| EPS Basic | -1.01 | 0.30 | -1.01 | -0.98 | -0.86 |
| Normalized Basic EPS | -0.63 | 0.19 | -0.61 | -0.61 | -0.54 |
| EPS Diluted | -1.01 | 0.30 | -1.01 | -0.98 | -0.86 |
| Normalized Diluted EPS | -0.63 | 0.19 | -0.61 | -0.61 | -0.54 |
| Average Basic Shares Outstanding | 68.06M | 63.92M | 56.13M | 55.93M | 55.74M |
| Average Diluted Shares Outstanding | 68.06M | 63.92M | 56.13M | 55.93M | 55.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |